COLUMBUS, Wis., Feb. 10, 2022 /PRNewswire-PRWeb/ — After nearly 44 years in business, Columbus Chemical Industries (CCI) has transitioned to a 100% ESOP (Employee Stock Ownership Plan) owned company. In an announcement made on January 27, 2022, company founder, Richard Sheard outlined how important it was that the CCI employees who helped grow a strong, prosperous company should share in its ownership into the future.
In the announcement meeting, after expressing his gratitude for efforts by the CCI team, but before telling employees that the company was sold to the ESOP, Richard stated along with the other Shareholders he had sold the company. After a pause, he then went on to unveil that the new owners were the employees, to which there was applause and amazement.
Thanking Richard and the shareholders for making such a wonderful decision to benefit the long-term future of CCI and all its associates, President Randall Eppli indicated Richard’s legacy of serving customers and honoring CCI associates will carry-on through an employee-owned company.
About CCI: With facilities in Wisconsin and Arizona and distributor partners reaching global customers, CCI is a specialty chemical company providing custom engineered solutions for the semiconductor, medical device, biotech, laboratory and industrial manufacturing industries. The CCI team is proud of the recognition regularly received for employee safety, outstanding service, environmentally conscious practices and active community involvement.
For more information on CCI’s transition to an ESOP contact Melissa Hoglund at: ESOP@ColumbusChemical.com.
More information on Columbus Chemical Industries can be found on the CCI website at: http://www.columbuschemical.com.
Media Contact
Melanie Matulonis, Marketing Team Leader, ESOP Partners, +1 (920) 750-5799, mmatulonis@esoppartners.com
SOURCE Columbus Chemical Industries, Inc.
CHICAGO, July 4, 2024 /PRNewswire/ -- The global microscopy market is poised for significant growth, expected…
Toronto, Ontario--(Newsfile Corp. - July 4, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE)…
MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) -- Global biotechnology leader CSL Behring (ASX: CSL)…
SKYSCRAPER-06 evaluating tiragolumab plus Tecentriq and chemotherapy did not meet the primary endpoints of progression-free…
ICPO Center NuMeRI ICPO Foundation signed the contract with Nuclear Medicine Research Infrastructure (NuMeRI) to…
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM)…